JP2015506942A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506942A5 JP2015506942A5 JP2014553292A JP2014553292A JP2015506942A5 JP 2015506942 A5 JP2015506942 A5 JP 2015506942A5 JP 2014553292 A JP2014553292 A JP 2014553292A JP 2014553292 A JP2014553292 A JP 2014553292A JP 2015506942 A5 JP2015506942 A5 JP 2015506942A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- fragment
- pharmaceutical composition
- apolipoprotein
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010073614 apolipoprotein A-IV Proteins 0.000 claims description 70
- 102100037320 Apolipoprotein A-IV Human genes 0.000 claims description 67
- 239000012634 fragment Substances 0.000 claims description 58
- 239000008194 pharmaceutical composition Substances 0.000 claims description 45
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 241000701447 unidentified baculovirus Species 0.000 claims description 3
- 108010071619 Apolipoproteins Proteins 0.000 claims description 2
- 102000007592 Apolipoproteins Human genes 0.000 claims description 2
- 239000013011 aqueous formulation Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 239000012931 lyophilized formulation Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 39
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2012/021802 | 2012-01-19 | ||
| PCT/US2012/021802 WO2012100010A1 (en) | 2011-01-19 | 2012-01-19 | Apolipoprotein aiv as an antidiabetic peptide |
| US201261675692P | 2012-07-25 | 2012-07-25 | |
| US61/675,692 | 2012-07-25 | ||
| PCT/US2012/066314 WO2013109342A1 (en) | 2012-01-19 | 2012-11-21 | Method of treating diabetes using non-glycosylated apolipoprotein a-iv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506942A JP2015506942A (ja) | 2015-03-05 |
| JP2015506942A5 true JP2015506942A5 (OSRAM) | 2016-01-21 |
| JP6310398B2 JP6310398B2 (ja) | 2018-04-11 |
Family
ID=48799573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553292A Expired - Fee Related JP6310398B2 (ja) | 2012-01-19 | 2012-11-21 | 非グリコシル化アポリポタンパク質ａ−ｉｖを用いて糖尿病を処置する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9951120B2 (OSRAM) |
| EP (1) | EP2804618B1 (OSRAM) |
| JP (1) | JP6310398B2 (OSRAM) |
| KR (1) | KR20140117565A (OSRAM) |
| CN (1) | CN104066436B (OSRAM) |
| AU (1) | AU2012366182B2 (OSRAM) |
| BR (1) | BR112014017141A2 (OSRAM) |
| CA (1) | CA2860782A1 (OSRAM) |
| EA (1) | EA028230B1 (OSRAM) |
| HK (1) | HK1203823A1 (OSRAM) |
| IL (1) | IL233351A (OSRAM) |
| MX (1) | MX357071B (OSRAM) |
| WO (1) | WO2013109342A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA028218B1 (ru) | 2011-01-19 | 2017-10-31 | Юниверсити Оф Цинциннати | Аполипопротеин a-iv в качестве противодиабетического пептида |
| EA028230B1 (ru) | 2012-01-19 | 2017-10-31 | Юниверсити Оф Цинциннати | Применение негликозилированного белка аполипопротеина a-iv для лечения сахарного диабета 2 типа |
| AU2012385960B2 (en) | 2012-07-25 | 2017-04-13 | University Of Cincinnati | Method of treating hyperglycemic disorders using apolipoprotein AIV |
| EP2877197A2 (en) * | 2012-07-25 | 2015-06-03 | University Of Cincinnati | Method of treating type i diabetes using apolipoprotein aiv |
| EP3159354B1 (en) * | 2014-06-23 | 2020-09-09 | Toagosei Co., Ltd. | Novel synthetic peptide and use thereof |
| CN112546201A (zh) * | 2019-09-26 | 2021-03-26 | 中国科学院生物物理研究所 | 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用 |
| CN113018459A (zh) * | 2021-03-09 | 2021-06-25 | 百码科技(深圳)有限公司 | 一种基因治疗减肥的生物药剂及其制备方法 |
| CN112891561A (zh) * | 2021-03-09 | 2021-06-04 | 百码科技(深圳)有限公司 | 一种基因治疗脂肪肝的生物药剂及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| FR2686605B1 (fr) * | 1992-01-27 | 1994-03-11 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides, leur preparation et leur utilisation. |
| AU7242394A (en) | 1993-05-28 | 1994-12-20 | Merck & Co., Inc. | Method to control appetite and treat obesity |
| US6729075B2 (en) * | 2000-10-19 | 2004-05-04 | Wenger Corporation | Audience seating system |
| EP1556413A4 (en) | 2002-05-17 | 2009-07-08 | Esperion Therapeutics Inc | METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC REPERFUSION |
| WO2008008357A1 (en) * | 2006-07-11 | 2008-01-17 | Harkness Pharmaceuticals, Inc. | Methods of treating obesity using satiety factors |
| US20100267052A1 (en) | 2006-09-01 | 2010-10-21 | American Type Culture Collection | Compositions and methods for diagnosis and treatment of type 2 diabetes |
| EP2257814B1 (en) * | 2008-03-21 | 2012-08-29 | Podiceps B.v. | Diagnostic of pre-symptomatic metabolic syndrome |
| CN103833713B (zh) | 2008-11-28 | 2016-02-03 | 中国医学科学院药物研究所 | 硝克柳胺化合物晶iii型、其制法和其药物组合物与用途 |
| JP5798193B2 (ja) * | 2010-08-30 | 2015-10-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アルカリ性フィード |
| EA028218B1 (ru) | 2011-01-19 | 2017-10-31 | Юниверсити Оф Цинциннати | Аполипопротеин a-iv в качестве противодиабетического пептида |
| EA028230B1 (ru) | 2012-01-19 | 2017-10-31 | Юниверсити Оф Цинциннати | Применение негликозилированного белка аполипопротеина a-iv для лечения сахарного диабета 2 типа |
| EP2877197A2 (en) | 2012-07-25 | 2015-06-03 | University Of Cincinnati | Method of treating type i diabetes using apolipoprotein aiv |
| AU2012385960B2 (en) * | 2012-07-25 | 2017-04-13 | University Of Cincinnati | Method of treating hyperglycemic disorders using apolipoprotein AIV |
-
2012
- 2012-11-21 EA EA201491369A patent/EA028230B1/ru not_active IP Right Cessation
- 2012-11-21 US US14/373,259 patent/US9951120B2/en active Active
- 2012-11-21 CA CA2860782A patent/CA2860782A1/en not_active Abandoned
- 2012-11-21 BR BR112014017141A patent/BR112014017141A2/pt not_active IP Right Cessation
- 2012-11-21 KR KR1020147023031A patent/KR20140117565A/ko not_active Withdrawn
- 2012-11-21 MX MX2014008829A patent/MX357071B/es active IP Right Grant
- 2012-11-21 WO PCT/US2012/066314 patent/WO2013109342A1/en not_active Ceased
- 2012-11-21 HK HK15104317.1A patent/HK1203823A1/xx unknown
- 2012-11-21 EP EP12795976.5A patent/EP2804618B1/en active Active
- 2012-11-21 AU AU2012366182A patent/AU2012366182B2/en not_active Expired - Fee Related
- 2012-11-21 JP JP2014553292A patent/JP6310398B2/ja not_active Expired - Fee Related
- 2012-11-21 CN CN201280067554.2A patent/CN104066436B/zh not_active Expired - Fee Related
-
2014
- 2014-06-24 IL IL233351A patent/IL233351A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506942A5 (OSRAM) | ||
| US20250360078A1 (en) | Extended release of neuregulin for treating heart failure | |
| ES2332057T3 (es) | Muteinas del factor de crecimiento de fibroblastos 21. | |
| US10786551B2 (en) | Use of interleukin-22 in the treatment of fatty liver disease | |
| Rodbard et al. | Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials | |
| Sousa et al. | How to overcome the limitations of current insulin administration with new non-invasive delivery systems | |
| JP2010031018A5 (OSRAM) | ||
| Bode | Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues—aspart, lispro, and glulisine | |
| CN101883609A (zh) | 可注射的速效胰岛素组合物 | |
| WO2001000223A2 (en) | Multiple agent diabetes therapy | |
| JP2016514132A5 (OSRAM) | ||
| JP2014504601A5 (OSRAM) | ||
| JP2020502150A5 (OSRAM) | ||
| Woo | A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus | |
| RU2004114865A (ru) | Композиция и способ лечения диабета | |
| CA2543507A1 (en) | Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions | |
| RU2020140694A (ru) | Способ лечения гипергликемии | |
| JP2015524808A5 (OSRAM) | ||
| JP2015524432A5 (OSRAM) | ||
| JP5732691B2 (ja) | インスリン製剤 | |
| EP3402505B1 (en) | Pharmaceutical formulations for the treatment of diabetes | |
| Henry et al. | Epoetin alfa for treatment of anemia in HIV-infected patients: past, present, and future | |
| Singhai et al. | Comparison of insulin glargine with human premix insulin in patients with type 2 diabetes inadequately controlled on oral hypoglycemic drugs in a 24-week randomized study among Indian population | |
| EP3655021A1 (en) | Adenosine deaminase for treating or ameliorating scleroderma-associated vasculopathy | |
| KR20190053461A (ko) | 열 안정성이 확보된 상피세포 성장인자 함유 창상 치료용 약학적 조성물 |